Clinical Trial

A Study on Bioequivalence of Cabergoline Tablets in Human Body

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 17, 2025 (before its estimated February 3, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the bioequivalence of the test formulation and reference formulation of cabergoline tablets in healthy Chinese subjects under fasting and postprandial conditions.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-05; most recent amendment 2025-11-14.
Status change: Recruiting → Active, Not Recruiting 2025-11-14
Status change: Not Yet Recruiting → Recruiting 2025-07-04
Trial Details
NCT Number NCT07008417
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions Hyperprolactinemia
Enrollment 72 participants
Start Date 2025-06-30
Primary Completion 2026-02-03 (estimated)
Study Completion 2026-05-06 (estimated)
Updated on ClinicalTrials.gov 2025-11-17